Genetically engineered immune system fights melanoma
2012-10-01
(Press-News.org) MAYWOOD, Il. - Loyola University Medical Center has launched the first clinical trial in the Midwest of an experimental melanoma treatment that genetically engineers a patient's immune system to fight the deadly cancer.
A batch of the immune system's killer T cells will be removed from the patient and genetically modified in a Loyola lab. Two genes will be inserted into the T cells so that they will recognize tumor cells as abnormal.
The patient will undergo high-dose chemotherapy to kill most of his or her remaining T cells. This will make room for the genetically modified T cells when they are put back in the patient. The modified T cells, it is hoped, will recognize the tumor cells as abnormal and then attack and kill them.
"This clinical trial is a unique attempt to manipulate a person's own immune system to attack their cancer in a more effective and specific manner," said Joseph Clark, MD, one of the principal investigators of the trial.
The purpose of the Phase 1 trial is to determine the optimum dose and whether the treatment is safe. Four doses will be tested, with the highest dose consisting of about 5 billion genetically modified T cells. If Phase 1 demonstrates the treatment is safe, investigators will proceed to Phase 2, which will determine whether the treatment is effective.
Melanoma is the sixth-most-common cancer in Americans, and the most common fatal malignancy in young adults. Incidence is rising dramatically. About 1 in 50 people will be diagnosed with melanoma. In the 1960s, it was 1 in 600.
Surgery is highly successful if the cancer is caught early. But if the cancer has spread to other parts of the body, the five-year survival rate is only 15 to 20 percent, according to the American Cancer Society.
"This is a terrible, devastating disease," Clark said. "It starts on the skin and can spread to just about anywhere in the body."
The clinical trial is open to patients with metastatic melanoma who are no longer responding to standard therapy. "We need better treatments," Clark said. "Our clinical trial is designed for patients who have no other options."
The experimental immune system therapy was developed by Michael I. Nishimura, PhD, director of the Immunotherapeutics Program at Loyola's Cardinal Bernardin Cancer Center. The cells will be prepared in the Robert R. McCormick Foundation Center for Cellular Therapy in the Bernardin Cancer Center.
Nishimura is principal investigator of a five-year, $16.3 million grant from the National Cancer Institute. "Our goal is to create novel therapies for the treatment of advanced malignancies," he said.
Additional funding for the trial comes from a National Cancer Institute grant to Lentigen Corp., which makes the vector that delivers the genes to the T cells, and from the American Recovery and Reinvestment Act (the economic stimulus bill).
Clark is a professor in the Department of Medicine, Division of Hematology/Oncology of Loyola University Stritch School of Medicine. Nishimura is a professor in the Department of Surgery and associate director of the Oncology Institute of Loyola University Chicago Stritch School of Medicine.
###
Other investigators in the trial are Patrick Stiff, MD, director of the Bernardin center; Constantine Godellas, MD; Kelli Hutchens, MD; and Caroline Le Poole, PhD.
For more information, call 708-327-3221.
ELSE PRESS RELEASES FROM THIS DATE:
AGU journal highlights -- 1 October 2012
2012-10-01
The following highlights summarize research papers that have been recently
published in Geophysical Research Letters (GRL), Journal of Geophysical
Research - Solid Earth (JGR-B), Journal of Geophysical Research - Oceans
(JGR-C), and Water Resources Research (WRR).
In this release:
1. The pros and cons of trading water: A case study in Australia
2. Linking typhoon tracks with rainfall patterns and flood timing
3. Novel observations of currents and drag generated by a tsunami
4. More water stored along major rivers during El Nino years
5. Model suggests Earth ...
New insights on control of pituitary hormone outside of brain has implications for breast cancer
2012-10-01
PHILADELPHIA - The hormone prolactin is produced by the pituitary gland in the brain and then travels via the bloodstream to cells throughout the body, where it exerts multiple reproductive and metabolic effects, most notably on the breast where it is the master regulator of lactation. In recent years researchers have found that prolactin is also produced by some tissues outside the brain, however little is known about the functions of extra-pituitary prolactin or how its production is regulated in these tissues.
Now, the laboratory of Lewis A. Chodosh, MD, PhD, chair ...
Fish getting smaller as the oceans warm: UBC research
2012-10-01
Changes in ocean and climate systems could lead to smaller fish, according to a new study led by fisheries scientists at the University of British Columbia.
The study, published today in the journal Nature Climate Change, provides the first-ever global projection of the potential reduction in the maximum size of fish in a warmer and less-oxygenated ocean.
The researchers used computer modeling to study more than 600 species of fish from oceans around the world and found that the maximum body weight they can reach could decline by 14-20 per cent between years 2000 and ...
Researchers discover key mechanism for controlling the body's inflammatory response
2012-10-01
Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can damage the organism. The findings, published in Nature Immunology today (30 September), could be exploited in vaccine development and new cancer therapies.
A healthy immune system reacts to danger signals – from microorganisms such as bacteria and viruses, or from the body's own rogue cells, such as cancer cells. This tightly controlled reaction starts ...
Researchers discover gene that causes deafness
2012-10-01
CINCINNATI—Researchers at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have found a new genetic mutation responsible for deafness and hearing loss associated with Usher syndrome type 1.
These findings, published in the Sept. 30 advance online edition of the journal Nature Genetics, could help researchers develop new therapeutic targets for those at risk for this syndrome.
Partners in the study included the National Institute on Deafness and other Communication Disorders (NIDCD), Baylor College of Medicine and the University of ...
New pathogen epidemic identified in sub-Saharan Africa
2012-10-01
A new study out today (Sunday 30 September) reveals that the emergence and spread of a rapidly evolving invasive intestinal disease, that has a significant mortality rate (up to 45%) in infected people in sub-Saharan Africa, seems to have been potentiated by the HIV epidemic in Africa.
The team found that invasive non-Typhoidal Salmonella (iNTS) disease is caused by a new form of the bacteria Salmonella Typhimurium that has spread from two different focal hubs in Southern and Central Africa beginning 52 and 35 years ago, respectively. They also found that one of the ...
Climate change could cripple southwestern forests
2012-10-01
Combine the tree-ring growth record with historical information, climate records, and computer-model projections of future climate trends, and you get a grim picture for the future of trees in the southwestern United States. That's the word from a team of scientists from Los Alamos National Laboratory, the U.S. Geological Survey, the University of Arizona, and other partner organizations.
If the Southwest is warmer and drier in the near future, widespread tree death is likely and would cause substantial changes in the distribution of forests and of species, the researchers ...
Common RNA pathway found in ALS and dementia
2012-10-01
Two proteins previously found to contribute to ALS, also known as Lou Gehrig's disease, have divergent roles. But a new study, led by researchers at the Department of Cellular and Molecular Medicine at the University of California, San Diego School of Medicine, shows that a common pathway links them.
The discovery reveals a small set of target genes that could be used to measure the health of motor neurons, and provides a useful tool for development of new pharmaceuticals to treat the devastating disorder, which currently has no treatment or cure.
Funded in part by ...
The genetics of white finger disease
2012-10-01
Vibration-induced white finger disease (VWF) is caused by continued use of vibrating hand held machinery (high frequency vibration >50 Hz), and affects tens of thousands of people. New research published in BioMed Central's open access journal Clinical Epigenetics finds that people with a genetic polymorphism (A2191G) in sirtuin1 (SIRT1), a protein involved in the regulation of endothelial NOS (eNOS), are more likely to suffer from vibration-induced white finger disease.
VWF (also known as hand arm vibration syndrome (HAVS)) is a secondary form of Raynaud's disease involving ...
Breast cancer recurrence defined by hormone receptor status
2012-10-01
Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research shows that women whose HER2 positive cancer was also hormone (estrogen and progesterone) receptor (HR) negative had an increased risk of early death, and that their cancer was less likely to recur in bone than those whose cancer retained hormone sensitivity.
Breast cancer is a heterogeneous disease with many different subtypes. HR positive cancer ...